Holen Sie sich die Stockscreener-App
381.00
1.69%
-6.54
Vorhandelsmarkt:
381.00
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - Yahoo! Finance Canada
BIO: Multi-year transformation leverages technology, M&A, and restructuring to drive growth and margin expansion - TradingView
BIO: Multi-year transformation leverages digital PCR leadership and targeted M&A for growth - TradingView
Bio-Rad at bernstein healthcare forum: shift toward profitable growth - Investing.com
Bio-Rad at bernstein healthcare forum: shift toward profitable growth By Investing.com - Investing.com Canada
Bio-Rad Laboratories, Inc. at Bernstein Insights Healthcare Leaders and Disruptors Transcript - gurufocus.com
Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher - Yahoo Finance
Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher - Investing.com
Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher By Investing.com - Investing.com India
Biodesix Announces Progress on Tumor-Informed and Tumor-Naïve MRD Programs with Bio-Rad and Thermo Fisher - Quiver Quantitative
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring - The Manila Times
Bio-Rad Laboratories, Inc. (BIO-B) Stock Price, News, Quote & History - Yahoo! Finance Canada
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now - Zacks Investment Research
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now - TradingView
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating Challenges in the Medical Devices Sector - DirectorsTalk Interviews
Bio-rad Laboratories Stock Price Forecast. Should You Buy BIO? - StockInvest.us
Accelerating Legacy .NET Modernization at Bio-Rad with AWS Transform and Kiro - Amazon Web Services (AWS)
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum - Investing News Network
Bio Rad (BIO) Stock Could Be 23% Overvalued As Column Expansion Continues - Yahoo Finance
Bio-Rad Laboratories, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
BIO-RAD LABORATORIES (NYSE: BIO) Grants 719 Derivative Securities to Director Allison Schwartz - Kalkine Media
BIO-RAD LABORATORIES Executive Evran Sedat Reports Exercising 3,880 Shares (NYSE: BIO) - Kalkine Media
Bio-Rad: Favorable Read-Across From Investor Event (NYSE:BIO) - Seeking Alpha
Bio-Rad (NYSE: BIO) director sees 320 RSUs convert, 116 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) EVP logs 4,313 RSU grant and 2,179 vested shares - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
1,453 stock units vest for Bio-Rad (NYSE: BIO) insider as 551 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) grants EVP 4,601 RSUs, with shares withheld at $386.11 - Stock Titan
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com Canada
Bio-Rad Terminates Forbes Tate Lobbying Pact - Legis1
Bio-Rad expands range of Foresight prepacked chromatography columns for biomanufacturing - selectscience.net
Chromatography Reagents Market 2026-2030 | Global key Player; - openPR.com
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating Current Market Challenges with Strategic Insights - DirectorsTalk Interviews
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - morningstar.com
BIO-RAD (NYSE: BIO) Director Allison Schwartz Reports 1,573 Shares Following Option Exercise - Kalkine Media
Mesa Laboratories Inc. (MLAB) Peer Comparison – Compare with Others - Value Research
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Bio-Rad Laboratories Inc. Class A (BIO) Key Financial Ratios – Valuation, Profitability & More - Value Research
RSU vesting gives Bio-Rad (NYSE: BIO) exec 425 shares - Stock Titan
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue? - finance.yahoo.com
Bio-Rad expands Foresight Pro prepacked chromatography columns with Nuvia ion exchange and mixed-mode resins - Manufacturing Chemist
Allied Healthcare Products Inc. (AHPI) Peer Comparison – Compare with Others - Value Research
Best Practices for qPCR Assay Design and Optimization - the-scientist.com
Bio-Rad expands Foresight Pro Prepacked Chromatography Columns with Nuvia Ion Exchange and Mixed-Mode Resins for Biomanufacturing - Cambridge Network
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference - Investing News Network
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a Challenging Market with a -15.14% Potential Downside - DirectorsTalk Interviews
Bio-Rad Laboratories Inc. Class A (BIO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Discipline and Rules-Based Execution in BIO Response - Stock Traders Daily
Bio-Rad Laboratories stock hits 52-week high at 394.22 USD - Investing.com Nigeria
Bio-Rad Laboratories (BIO) Edges Lower to $388.77 as Shares Consolidate Between Key Support and ResistanceWyckoff Upthrust - careplusvn.com
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating the Upside Amidst Market Challenges - DirectorsTalk Interviews
Why Bio-Rad Laboratories (BIO) Is Up 6.7% After Restructuring Move Amid Mixed Segment Trends - Sahm
Return on invested capital % of Bio-Rad Laboratories, Inc. Class A – HAM:BUWA - TradingView
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation? - Yahoo Finance
1.51%
0.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):